Theravance Biopharma Inc's Competitiveness
A competitive positioning analysis and financial ratio benchmarking of Theravance Biopharma Inc (TBPH) against its publicly traded competitors: sales growth, net income, profitability, valuation and market share, plus each peer's market capitalization, revenue, income and employees. Free below: the top 5 peers. Subscriber access adds the full competitor list and CSV downloads.
Key Findings: Theravance Biopharma Inc vs Its Competitors
- TTM: Trailing 12-month revenue of 104M vs 530,405M combined for its competitors (0.0% combined share).
- Trending: Latest-quarter revenue run-rate is decelerating (-20.5% annualized vs trailing 12 months), vs accelerating (+2.4%) for its tracked peer group.
- Growth: Theravance Biopharma Inc generated -20.9% revenue growth year over year in Q2 2026, vs 13.1% for its competitors combined.
- Profitability: Its -28.5% net margin compares with 4.9% for the peer group.
- Peer revenue share: Theravance Biopharma Inc accounted for 0.0% of combined revenue among its tracked peer group, up from 0.0% a year earlier.
- Peer differentiation: Revenue per employee of $1.16M compares with $0.98M for the peer group (1.2x).
- Structure: Theravance Biopharma Inc operates in the following segments: Single reportable segment.
Every figure above is sourced and cited in detail further down this page (Market Structure, Profitability & Cost Structure, Productivity vs Peers).
TBPH Sales vs. its Competitors, Q2 2026
Theravance Biopharma Inc reported revenue contraction of 20.86 % year on year in Q2 2026, below its competitors' combined revenue growth of 13.09 %.
With a net margin of -28.45 %, Theravance Biopharma Inc reported lower profitability than its competitors (4.90 %).
Theravance Biopharma Inc generated 0.02 % of the combined sales of its peer group, up from 0.02 % a year earlier.
API endpoints for this dataset
Theravance Biopharma Inc vs. its Competitors, Q2 2026
Revenue growth, year on year
Net margin
Revenue run-rate vs trailing 12 months
TTM net margin
TTM = trailing twelve months. Run-rate annualizes the latest quarter (×4) and compares it to TTM. In millions of $. High-Confidence Competitors are named as a competitor directly in Theravance Biopharma Inc reports; Similar-Size Competitors are the closest peers by market-cap rank within the same industry; Similar Growth & Profitability Competitors are the closest peers by combined revenue growth, operating margin and ROIC, all independent of the competitor list.
TTM revenue, latest-quarter run-rate and net income/margin benchmarked across Theravance Biopharma Inc and its 4 competitor groupings. Available under Commercial License.
| Entity | TTM Revenue | Rev Run-rate vs TTM |
|---|---|---|
| Theravance Biopharma inc | $12,345M | +12.3% · Accelerating |
| Competitors combined | $12,345M | +12.3% · Accelerating |
TTM revenue, run-rate and net margin benchmarking across Theravance Biopharma Inc's competitor groups requires a Commercial License.
For context: the Major Pharmaceutical Preparations industry grew revenue 8.9% year over year, combined, vs -20.9% for Theravance Biopharma Inc. Theravance Biopharma Inc's share of combined industry revenue moved from 0.01% to 0.00%, a gain of 0.00 percentage points.
Theravance Biopharma Inc's Competitor Quality Breadth
Group definitions: see Methodology: Performance Group Definitions.
| Entity | Profitable | Expanding | Above Industry Growth | Distressed |
|---|---|---|---|---|
| Theravance Biopharma inc | Yes | Yes | Yes | No |
| Competitors combined (91) | ||||
| High-Confidence Competitors (2) |
Source: CSIMarket API, trailing 12 months. Altman Z-Score is not shown here: it is not populated in the underlying data for any company. Percentages are of companies in each group that report the relevant metric, not of the full group size.
TBPH Stock Performance relative to its Competitors
TBPH Stock Performance relative to High-Confidence Competitors
5 Best-Performing Tracked Competitors, Trailing 12 Months
| # | Competitor | TTM Share Price Return | vs U.S.A. 500 |
|---|---|---|---|
| 1 | Moderna Inc | 282.9% | Outperformed |
| 2 | Climb Bio Inc | 282.9% | Outperformed |
| 3 | Gossamer Bio Inc | 282.9% | Outperformed |
| 4 | An2 Therapeutics Inc | 282.9% | Outperformed |
| 5 | Prelude Therapeutics Inc | 282.9% | Outperformed |
TTM share price return and U.S.A. 500 outperformance for Theravance Biopharma Inc's best-performing competitors requires a Commercial License.
Source: CSIMarket API, trailing 12 months.
Theravance Biopharma Inc's Comment on Competition and Industry Peers
Publicly Traded Peers of Theravance Biopharma inc
Revenue and income for trailing 12 months, in millions of $, except employees| Company | Market Cap | Revenues |
|---|---|---|
 Theravance Biopharma inc |
879.89 | 104.31 |
 Eli Lilly And Company |
1,261,319.90 | 86,462.00 |
 Johnson and Johnson |
690,774.55 | 99,335.00 |
 Beone Medicines Ltd |
628,232.68 | 6,128.24 |
 Merck and Co Inc |
367,313.70 | 66,569.00 |
 Novartis Ag |
320,013.95 | 56,674.00 |
| SUBTOTAL | 5,037,787.92 | 730,012.82 |
Sign in to see all competitors of Theravance Biopharma inc .
Sources: see Methodology: Peer & Competitor Identification, Sourcing.
Updated on:
Focus of this report: publicly traded companies. Ten additional tables on Theravance Biopharma inc versus competitors, including market share analysis, are in the navigation menu under Competition. To download the tables, please subscribe.
Theravance Biopharma Inc's Competitors Named by the Company
Competitive relationships identified from Theravance Biopharma Inc reports and corroborating sources, each with a basis and confidence.| Competitor | Basis | Confidence |
|---|---|---|
| Novartis | Company report | 85% |
| AstraZeneca | Company report | 85% |
| Chiesi Farmaceutici | Company report | 85% |
| Medicines Co | Company report | 85% |
| Alkermes Plc | Company report | 85% |
| Regeneron Pharmaceuticals Inc | Company report | 85% |
| Gilead Sciences Inc | Company report | 85% |
| Amgen Inc | Company report | 85% |
| Vertex Pharmaceuticals Inc | Company report | 85% |
| Eli Lilly And Company | Company report | 85% |
| Cerevel Therapeutics Holdings Inc | Company report | 85% |
| Liquidia Corporation | Company report | 85% |
Company report basis, confidence, active dates and source counts for Theravance Biopharma Inc's named competitors require a Commercial License.
Methodology: see Methodology: Peer & Competitor Identification, Sourcing.
Theravance Biopharma Inc's Business Segment Mix vs Peers
Revenue by operating segment or division, as named and reported by each company. Segment names are the filer's own and are not standardized across companies. Do not assume a same-named or similarly-named segment is defined identically between two companies. Shares are of each company's own total revenue and are not required to sum to 100% (intersegment revenue, unallocated items).| Company | Largest Segment |
|---|---|
| Theravance Biopharma inc | Single reportable segment 100.00 % |
| Eli Lilly And Company | Reportable 100.00 % |
| Johnson and Johnson | Oncology 29.93 % |
| Merck and Co Inc | Pharmaceutical segment 89.95 % |
| Amgen Inc | Reportable 100.00 % |
| Pfizer Inc | U.S. Commercial Division 58.35 % |
Source: operating segment revenue as reported in each company's reports (10-K/10-Q), via the CSIMarket API, leaf-level reportable segments only (parent roll-up segments are excluded where sub-segments are separately disclosed).
Sign in to see all peers for Theravance Biopharma inc .
Theravance Biopharma Inc's Productivity vs Peers Comparison
Revenue and income per employee, trailing 12 months, in $; market cap in millions of $| Company | Market Cap | Revenue / Employee | Income / Employee |
|---|---|---|---|
| Theravance Biopharma inc | 880 | 1,159,011 | 597,867 |
| Eli Lilly And Company | 1,261,320 | 1,729,240 | 551,594 |
| Johnson and Johnson | 690,775 | 705,504 | 114,311 |
| Beone Medicines Ltd | 628,233 | 510,686 | 54,642 |
| Merck and Co Inc | 367,314 | 887,587 | 42,267 |
| Novartis Ag | 320,014 | 752,973 | 185,566 |
| PEERS TOTAL | 5,036,908 | 982,577 | 138,718 |
Sign in to see all peers for Theravance Biopharma inc .
Theravance Biopharma Inc's Geographic Revenue Exposure vs Peers
Revenue by country/region as reported in each company's most recent report. Disclosure granularity varies by filer (some report by country, others by broad region) and is shown as disclosed.| Company | Largest Market |
|---|---|
| Eli Lilly And Company | United States 62.04 % |
| Johnson and Johnson | United States 58.90 % |
| Beone Medicines Ltd | United States 54.39 % |
| Merck and Co Inc | EMEA 21.50 % |
| Gilead Sciences Inc | United States 76.66 % |
Source: revenue geography as reported in each company's reports (10-K/10-Q), via the CSIMarket API. Percentages are of that company's own total consolidated revenue for its most recent reported period.
Sign in to see all peers for Theravance Biopharma inc .
Theravance Biopharma Inc's Position in Industry Market Structure
Market-capitalization share and concentration across all 495 companies in Theravance Biopharma Inc's industry classification, broader than the peer set above. Market cap in millions of $.Theravance Biopharma Inc ranks #0 of 495 companies by market capitalization in its industry, holding 0.00 % of total industry market cap. The industry's Herfindahl-Hirschman Index (HHI) is 888, indicating a unconcentrated market structure (see Methodology: Market Structure & Concentration).
| Rank | Company | Market Cap | Industry Share |
|---|---|---|---|
| 1 | Eli Lilly And Company | 1,261,743 | 21.10 % |
| 2 | Johnson and Johnson | 688,377 | 11.51 % |
| 3 | Beone Medicines Ltd | 628,233 | 10.51 % |
| 4 | Abbvie Inc | 519,434 | 8.69 % |
| 5 | Merck and Co Inc | 1,234 | 5.2% |
| 6 | Novartis Ag | 1,234 | 5.2% |
| 7 | Abbott Laboratories | 1,234 | 5.2% |
| 8 | Novo Nordisk A | 1,234 | 5.2% |
| 9 | Pfizer Inc | 1,234 | 5.2% |
| 10 | Astrazeneca Plc | 1,234 | 5.2% |
| 0 | Theravance Biopharma inc | 880 | 0.00 % |
Market cap and industry share for the rest of Theravance Biopharma Inc's industry peers requires a Commercial License.
Source: CSIMarket API (daily market-structure computation) across CSIMarket's industry classification, market capitalization as of 2026-09-25.
Theravance Biopharma Inc's Profitability & Cost Structure
Trailing 12-month margins from SEC-filed financials. Operating margin is compared to the Major Pharmaceutical Preparations industry median; gross margin, EBITDA margin and capital intensity are compared to the live industry average (445 companies). See the full Major Pharmaceutical Preparations industry profitability benchmarks.| Metric | Company | Industry | Difference |
|---|---|---|---|
| Gross Margin | - | 37.84 % (avg) | - |
| Operating Margin | - | industry median | - |
| EBITDA Margin | 0.59 % | -6.50 % (avg) | +7.1 pp |
| Capital Intensity (Capex / Revenue) | - | 7.56 % (avg) | - |
Source: CSIMarket API, trailing 12 months. SG&A and R&D as a share of revenue have limited coverage as this data is backfilled and appear only where reported. Higher capital intensity is not inherently negative; it reflects the industry's asset requirements.
Theravance Biopharma Inc's Valuation vs Competitive Position
Valuation multiples vs the Major Pharmaceutical Preparations industry average (445 companies, excluding loss-making/negative-equity outliers), alongside returns on capital for context on whether a premium or discount lines up with measurably stronger or weaker returns. See the full Major Pharmaceutical Preparations industry valuation benchmarks.| Metric | Company | Industry Average | Difference |
|---|---|---|---|
| P/E | 15.9x | 26.6x | -10.7x |
| EV / EBITDA | 9.8x | 15.5x | -5.7x |
| P/B | 3.1x | 4.3x | -1.2x |
| Return on Equity | 0.19 % | industry aggregate | -16.16 % |
| Return on Invested Capital | - | -9.84 % (avg) | - |
Source: CSIMarket API, trailing 12 months. A valuation premium or discount is not, by itself, a judgment of over- or under-valuation. Compare it against the return and growth context shown elsewhere on this page.
Theravance Biopharma Inc's Multi-Year Financial Trajectory
Fiscal-year revenue growth, operating margin, return on invested capital and P/E, as reported in company reports.| Metric | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue Growth | 500.00 % | 21.61 % | -2.12 % | -23.03 % | -7.17 % | 11.84 % | 12.12 % | 66.92 % |
| Operating Margin | -395.48 % | -343.14 % | -414.37 % | -466.06 % | -179.09 % | -97.58 % | -72.92 % | -3.35 % |
| Return on Invested Capital | -55.46 % | -128.64 % | - | - | -20.62 % | -9.48 % | -12.36 % | -0.78 % |
| P/E | - | - | - | - | 1.0x | - | - | 8.1x |
Source: CSIMarket API, fiscal-year figures. P/E is this company's own historical ratio at each fiscal year end and can swing sharply around an earnings trough: that is real, not a data error.
Theravance Biopharma Inc's Competitive Forces (Porter's Five Forces)
Only the forces this data can support honestly are shown; the other three are marked as such rather than guessed.| Force | Assessment | Basis |
|---|---|---|
| Competitive Rivalry | High | Industry HHI of 888 (see Industry Market Structure & Concentration above) |
Note: see Methodology: Porter's Five Forces. Supplier power and buyer power are covered on Theravance Biopharma Inc's dedicated Suppliers and Customers pages, not here.
Theravance Biopharma Inc's Industry Attractiveness & Competitive Strength
See Methodology: GE/McKinsey Matrix for how the two axes are built.
Theravance Biopharma Inc falls in the Low attractiveness / High strength cell: Selective.
Source: CSIMarket API, trailing 12 months. Each axis score is a simple 1(low)/2(medium)/3(high) average across its three inputs -- a transparent, disclosed simplification, not a validated academic scoring model.
Theravance Biopharma Inc's SWOT
Every point below is a fixed rule applied to a metric already shown elsewhere on this page (Market Structure, Profitability, Valuation, Run-Rate, Stock Performance, Quality Breadth) not an independent strategic assessment. A blank quadrant means no rule was met, not that none apply.Strengths
No rule matched.
Weaknesses
- Return on equity 16.2 points below the industry aggregate.
- Latest-quarter revenue run-rate is decelerating (-20.5% annualized vs trailing 12 months).
Opportunities
- A meaningful share of competitors (45.50 %) show financial-distress signals, a possible opening to gain share.
Threats
No rule matched.
Methodology: see Methodology: SWOT Analysis.
Theravance Biopharma Inc's Financial Strength vs Peers Comparison
Quick ratio, working capital, debt to equity and asset turnover, trailing 12 months| Company | Quick Ratio | Working Capital | Debt / Equity |
|---|---|---|---|
| Theravance Biopharma inc | 7.30 | 11.63 | - |
| Eli Lilly And Company | 0.16 | 1.44 | 1.44 |
| Johnson and Johnson | 0.36 | 1.04 | 0.60 |
| Beone Medicines Ltd | 2.30 | 3.16 | 0.23 |
| Merck and Co Inc | 0.40 | 1.46 | 1.01 |
| Novartis Ag | 0.42 | 1.12 | 0.02 |
Sign in to see all peers for Theravance Biopharma inc .
Quick ratio = cash / current liabilities; working capital ratio = current assets / current liabilities; asset turnover = revenue / total assets. Peers in the Blank Checks industry are excluded.
Theravance Biopharma Inc's Revenue and Income Growth vs Peers
Quarterly revenue and net income growth, year over year and quarter over quarter| Company | Period | Revenue Y/Y | Income Y/Y |
|---|---|---|---|
| Theravance Biopharma inc | Q2 2026 | -20.9 % | - |
| Eli Lilly And Company | Q3 2026 | +38.6 % | +15.6 % |
| Johnson and Johnson | Q3 2026 | +5.9 % | -95.9 % |
| Beone Medicines Ltd | Q2 2026 | +29.7 % | +151.3 % |
| Merck and Co Inc | Q2 2026 | +5.1 % | - |
| Novartis Ag | Q4 2025 | +9.6 % | +17.0 % |
| PEERS TOTAL | +9.9 % | -0.8 % |
Sign in to see all peers for Theravance Biopharma inc .
Growth is shown only where both periods are positive. Peers in the Blank Checks industry are excluded.
Theravance Biopharma Inc's Peers' Costs of Sales and Capital Expenditures
Context for revenue growth: peer costs and capex, year over year and quarter over quarter| Company | Period | Costs Y/Y | Capex Y/Y |
|---|---|---|---|
| Theravance Biopharma inc | Q2 2026 | - | - |
| Eli Lilly And Company | Q3 2026 | +30.7 % | +52.2 % |
| Johnson and Johnson | Q3 2026 | +10.9 % | +17.7 % |
| Beone Medicines Ltd | Q2 2026 | +6.4 % | -57.0 % |
| Merck and Co Inc | Q2 2026 | +23.6 % | +16.9 % |
| Novartis Ag | Q4 2025 | +18.3 % | +13.3 % |
Sign in to see all peers for Theravance Biopharma inc .
Theravance Biopharma Inc's Returns and Turnover vs Peers
ROA, ROI and ROE (trailing 12 months), receivables and inventory turnover| Company | ROA | ROI | ROE |
|---|---|---|---|
| Theravance Biopharma inc | 11.68% | 17.10% | 19.40% |
| Eli Lilly And Company | 21.24% | 32.00% | 83.65% |
| Johnson and Johnson | 8.06% | 10.53% | 19.55% |
| Beone Medicines Ltd | 7.82% | 10.32% | 14.24% |
| Merck and Co Inc | 2.42% | 3.24% | 6.59% |
| Novartis Ag | 12.59% | 12.62% | 30.00% |
Sign in to see all peers for Theravance Biopharma inc .
ROA = net income / total assets; ROI = net income / investments; ROE = net income / equity; turnover ratios use trailing 12 month revenue (receivables) and cost of sales (inventory).
Theravance Biopharma Inc's Valuation vs Peers
P/E, price to sales, PEG, price to cash flow and price to book| Company | P/E | Price / Sales |
|---|---|---|
| Theravance Biopharma inc | 16.38 | 8.44 |
| Eli Lilly And Company | 45.84 | 14.59 |
| Johnson and Johnson | 42.68 | 6.95 |
| Beone Medicines Ltd | 948.48 | 102.51 |
| Merck and Co Inc | 119.93 | 5.52 |
| Novartis Ag | 22.88 | 5.65 |
| PEERS AVERAGE | 48.86 | 6.90 |
Sign in to see all peers for Theravance Biopharma inc .
P/E = price / diluted EPS (trailing 12 months); PEG = P/E divided by EPS growth; the average row divides the peers' combined market cap by their combined income, sales, cash flow and equity.